Torch Five-Pathogen Panel Screening Test (TORCH Panel): A Comprehensive Technical Guide

The TORCH Five-Pathogen Panel Screening Test is a critical serological assay used to detect antibodies against Toxoplasma gondii, Rubella virus, Cytomegalovirus, and Herpes Simplex Virus types I and II in women planning pregnancy or during early pregnancy. This comprehensive guide explains the testing methodology, sample requirements, clinical interpretation, and applications of this essential preconception and prenatal screening tool.

Technical Overview

The TORCH Five-Pathogen Panel Screening Test, commonly referred to as the preconception five-item screening or eugenics panel, is a serological diagnostic assay designed to detect specific antibodies against five vertically transmissible pathogens: Toxoplasma gondii (TOX), Rubella virus (RV), Cytomegalovirus (CMV), and Herpes Simplex Virus types I and II (HSV-I and HSV-II). These pathogens are collectively known as TORCH agents, an acronym derived from Toxoplasma, Rubella, Cytomegalovirus, and Herpes, with additional pathogens historically grouped under "Other."

When a pregnant woman experiences a primary infection with any of these pathogens, the microorganisms may cross the placental barrier and cause congenital infection in the fetus. Depending on the pathogen and the gestational timing of infection, consequences may include miscarriage, stillbirth, fetal malformation, congenital anomalies, neurological impairment, hearing loss, visual defects, or long-term developmental delays. The panel therefore measures both IgM antibodies, which indicate recent or active infection, and IgG antibodies, which indicate past exposure and the presence of immunological memory.

Testing is recommended for women during preconception planning (ideally 3 to 6 months before pregnancy) and during early pregnancy. Preconception screening allows time for vaccination (in the case of Rubella), treatment, or informed pregnancy planning, while early prenatal screening enables timely clinical intervention and fetal monitoring.

Testing Samples

Serum (Primary Sample)

Venous blood is collected into a plain tube or separator tube, allowed to clot, and centrifuged to obtain serum. A volume of 2 to 5 mL is typically sufficient for the full five-pathogen panel with IgM and IgG determination. Serum samples are stable at 2–8°C for up to 48 to 72 hours; for longer storage, samples should be frozen at -20°C or below and protected from repeated freeze-thaw cycles. Hemolyzed, lipemic, or icteric samples may interfere with immunoassay results and should be avoided or noted.

Plasma

Plasma collected in tubes containing EDTA or heparin anticoagulant is acceptable for most chemiluminescent immunoassay (CLIA) platforms. The laboratory should verify compatibility between the anticoagulant and the specific assay system in use.

Other Clinical Specimens (Supplementary)

In cases where congenital infection is suspected, additional specimen types may be tested to support diagnosis. These include amniotic fluid, cord blood, cerebrospinal fluid, urine, or neonatal blood, primarily analyzed using nucleic acid amplification methods such as PCR for direct pathogen detection.

Testing Items

The complete panel comprises ten antibody determinations, covering both IgM and IgG for each of the five pathogens:

• Toxoplasma gondii IgM (TOX-IgM) and IgG (TOX-IgG): Toxoplasma infection occurs through contact with cat feces, consumption of undercooked meat, or contaminated food and water. Primary infection during early pregnancy carries a risk of congenital toxoplasmosis, which may cause hydrocephalus, chorioretinitis, intracranial calcifications, and neurological damage.
• Rubella virus IgM (RV-IgM) and IgG (RV-IgG): Rubella infection during the first trimester carries the highest risk of Congenital Rubella Syndrome (CRS), characterized by cardiac defects, cataracts, sensorineural hearing loss, and growth retardation. IgG positivity indicates vaccine-induced or natural immunity, which is protective.
• Cytomegalovirus IgM (CMV-IgM) and IgG (CMV-IgG): CMV is the most common cause of congenital viral infection. Primary infection during pregnancy carries a 30–40% transmission risk, potentially leading to hearing loss, microcephaly, developmental delay, and thrombocytopenia in the newborn. CMV IgG avidity testing helps distinguish primary from non-primary infection.
• Herpes Simplex Virus type I IgM/IgG (HSV-I IgM/IgG): HSV-I primarily causes orolabial lesions but can be transmitted to the neonate during delivery, potentially causing neonatal herpes.
• Herpes Simplex Virus type II IgM/IgG (HSV-II IgM/IgG): HSV-II is associated with genital herpes and carries the highest risk of neonatal transmission during vaginal delivery when active lesions or viral shedding are present.

For each pathogen, the combination of IgM and IgG results supports interpretation of the infection status: IgM-negative/IgG-negative indicates susceptibility; IgM-negative/IgG-positive indicates past infection or immunity; IgM-positive/IgG-negative suggests early primary infection requiring confirmatory testing; and IgM-positive/IgG-positive suggests recent or active infection, which requires further evaluation such as avidity testing or nucleic acid detection.

Testing Methods

Chemiluminescent Immunoassay (CLIA)

CLIA is currently the most widely adopted platform in clinical laboratories due to its high sensitivity, excellent specificity, wide dynamic range, full automation, and rapid turnaround time. The assay uses antigen-coated magnetic microparticles and acridinium ester-labeled conjugates to quantify specific IgM or IgG antibodies, with results reported as signal-to-cutoff (S/CO) ratios or quantitative concentration values.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA remains a cost-effective and reliable method, particularly in resource-limited settings. Indirect ELISA formats are used for antibody capture, with colorimetric detection measured by a microplate reader. It offers good throughput but requires more manual handling and longer incubation times compared to CLIA.

Immunoblot and Immunofluorescence Assay (IFA)

These methods are used primarily as confirmatory or supplementary tools when screening results are equivocal or discordant with the clinical picture.

PCR (Nucleic Acid Amplification Testing)

PCR provides direct pathogen detection and is indicated for confirming active infection, monitoring viral load, detecting congenital infection in neonates, and testing amniotic fluid following documented maternal seroconversion. Real-time quantitative PCR is the preferred format.

Quality Considerations

Laboratories must implement internal quality control with each run and participate in external quality assessment programs. IgM assays are susceptible to interference from rheumatoid factor and heterophilic antibodies, and false-positive IgM results are documented; therefore, positive IgM findings should be interpreted alongside IgG results, clinical context, and, when necessary, confirmatory testing on a follow-up sample collected 1 to 2 weeks later to demonstrate seroconversion or rising titers.

Applications

• Preconception screening: Assessing immune status in women planning pregnancy, allowing Rubella vaccination for non-immune individuals (with a recommended 1 to 3 month interval before conception) and health education regarding Toxoplasma prevention.
• Early prenatal screening: Identifying recent or active infections in the first trimester to guide further diagnostic workup, fetal monitoring, and potential therapeutic decisions.
• Diagnosis of congenital infection: Supporting the evaluation of suspected intrauterine infection, fetal abnormalities detected by ultrasound, or symptomatic neonates.
• High-risk population management: Screening of individuals with exposure to cats or raw meat, healthcare or childcare workers, patients with flu-like symptoms during pregnancy, and women with a history of adverse pregnancy outcomes.
• Guidance for delivery management: Identifying active genital HSV infection to inform decisions regarding cesarean delivery and neonatal prophylaxis.
• Immunity documentation: Confirming protective Rubella immunity to reassure patients and clinicians and to prioritize postpartum vaccination when non-immunity is identified.

FAQ

Q: When is the optimal time for TORCH screening?

A: Ideally, testing should be performed 3 to 6 months before conception. If not done preconception, it should be completed as early as possible in pregnancy, preferably during the first trimester.

Q: What does a positive IgM result mean?

A: A positive IgM result suggests a recent or active infection, but false positives can occur. Confirmation with repeat testing, IgG avidity testing, or PCR is recommended before clinical conclusions are drawn.

Q: If both IgM and IgG are negative, is that a problem?

A: No. This result indicates no prior exposure and no current infection. For Rubella, however, it means the woman is non-immune, and vaccination should be considered before pregnancy.

Q: Does a positive IgG result mean I cannot become pregnant?

A: No. IgG positivity indicates past infection or vaccination and generally reflects immunity. In most cases, this is a favorable result for pregnancy planning.

Q: Can TORCH infections be treated during pregnancy?

A: Yes, in select cases. For example, Spiramycin may be used for toxoplasmosis, and antiviral therapy is available for CMV and HSV under specialist guidance. Management decisions depend on the pathogen, gestational age, and confirmed infection status.

Q: Is fasting required before blood collection?

A: Fasting is not required. The assay measures antibodies, which are not affected by recent food intake, although standard venipuncture protocols should be followed.